Neuropathic Pain Clinical Trials 2023

Neuropathic Pain Clinical Trials 2023

Neuropathic Pain research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in neuropathic pain clinical trials today.

Neuropathic Pain Clinical Trials

Here are the 6 most popular medical studies for neuropathic pain

Popular filter options for neuropathic pain trials

Spinal Cord Injury Clinical Trials

View 16 Spinal Cord Injury medical studies.

CSCI Clinical Trials

View 16 CSCI medical studies.

Phase 3 Neuropathic Pain Clinical Trials

View 75 phase 3 neuropathic pain medical studies.

Calgary, Alberta

Cannabinoid

Nabilone for Diabetic Neuropathy

Recruiting2 awardsPhase 3
Calgary, Alberta

Neuropathic pain occurs as a result of damage or disease of the peripheral or central nervous system. Regardless of its cause, neuropathic pain (NeP) leads to a characteristic clinical picture characterized by ongoing pain with steady or dysesthetic pain, such as burning or aching, and paroxysmal pain such as shooting or stabbing. In conditions such as diabetic neuropathy, changes in the membrane-bound proteins that form ion channels may alter the electrical properties of the injured neuron, called remodeling. The net effect of membrane remodeling is greater excitability of neurons, leading to a tendency towards action potential generation and propagation in injured primary sensory neurons which occurs in the context of nerve injury and disease. Over the past decade, a new endogenous cannabinoid receptor-mediated system within the nervous system and upon immune-mediated cells has been described. The cannabinoid receptor system consists of two receptors, CB1 and CB2 receptors, as well as endogenously produced endocannabinoids which agonize these receptors. This is a multicenter trial amongst Western Canadian sites to compare the efficacy of nabilone versus placebo in treating patients with chronic neuropathic pain (NeP) due to diabetic peripheral neuropathy (DPN). A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate. All subjects will begin with nabilone therapy of 1 mg daily for a minimum of 4 days, with the dose of the study medication assessed and adjusted either upwards or downwards as needed to balance efficacy for pain control with tolerability of possible side effects. All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion of the study.

Neuropathic Pain Clinical Trials With No Placebo

View 75 neuropathic pain medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to neuropathic pain

What are the top hospitals conducting neuropathic pain research?

When it comes to finding new solutions for those suffering from neuropathic pain, several top hospitals are leading the way. Stanford University, located in both Stanford and Palo Alto, California, is at the forefront of this field with a total of five active neuropathic pain trials between its two campuses. Since recording their first trial in 2016 (Stanford) and 2022 (Palo Alto), they have demonstrated a commitment to advancing our understanding of this condition. Meanwhile, in Miami, Florida, the University of Miami has also emerged as an influential institution with three ongoing neuropathic pain trials and a record of four completed studies since initiating their first trial in 2017.

Heading north to Minneapolis, Minnesota, we find another prestigious facility making strides in neuropathic pain research. The University of Minnesota has successfully conducted five clinical trials on this subject thus far while currently running three more investigations. Their dedication began in 2016 when they embarked on their inaugural neuropathic pain study. Rounding off these pioneering hospitals is Massachusetts General Hospital in Boston—this renowned establishment has made significant contributions to addressing neuropathic pain through six completed clinical trials and continues their efforts with three ongoing studies since delving into this area back in2006.

These medical centers collectively represent beacons of hope for individuals enduring the challenges posed by chronic neuropathic pain—a condition that can greatly affect one's quality life.Through innovative research endeavors carried out across different locations nationwide,a shared goal remains: alleviating suffering,promoting better treatments,and improving overall well-being.As these institutions push boundaries and expand knowledge about managing patients' conditions,the potential for breakthroughs emerges ever closer,fueling optimism among countless individuals who eagerly await advancements that might transform their lives forever

Which are the best cities for neuropathic pain clinical trials?

In the realm of neuropathic pain clinical trials, several cities stand out as leading centers for research. Among them are Boston, Massachusetts with 11 active trials investigating treatments like Gabapentin and Qutenza (capsaicin) 8% topical system. Houston, Texas also joins the ranks with 10 ongoing studies focused on interventions such as Tetrodotoxin for injection. Additionally, Miami, Florida contributes to the field with 8 active trials exploring innovative solutions like Transcranial direct electrical stimulation (tDCS). These cities serve as key hubs where individuals suffering from neuropathic pain can find opportunities to participate in cutting-edge clinical trials that could potentially revolutionize treatment options and improve their quality of life.

Which are the top treatments for neuropathic pain being explored in clinical trials?

Clinical trials investigating treatments for neuropathic pain have identified several promising options. [18F]FTC-146, a drug first listed in 2018, is currently being explored in two active trials dedicated to neuropathic pain. Another effective approach is spinal cord stimulation, which has shown positive results in five all-time trials and is currently under investigation in two ongoing studies. Additionally, ketamine infusion therapy has emerged as a potential treatment option with one active trial and one all-time trial focused on neuropathic pain since its recent introduction in 2021. These innovative approaches offer hope for individuals suffering from this challenging condition.

What are the most recent clinical trials for neuropathic pain?

Exciting developments are underway in the field of neuropathic pain management, with recent clinical trials offering potential breakthroughs. One such trial explores the effectiveness of RTA 901 Dose 1 as a treatment for neuropathic pain. Additionally, Gabapentin has shown promising results in Phase 3 trials, indicating its potential to provide relief for individuals suffering from this condition. Another avenue being explored is the use of THC (Dronabinol) and CBD/PEA as alternative therapies for neuropathic pain management. Moreover, AFA-281 shows promise in early-phase studies as a potential solution to alleviate neuropathic pain symptoms. These ongoing trials hold great promise and offer hope to those experiencing the debilitating effects of neuropathy-related discomfort.

What neuropathic pain clinical trials were recently completed?

In recent years, numerous clinical trials have been conducted to explore potential treatments for neuropathic pain. Notable among these trials are the completion of a study on LY3526318 by Eli Lilly and Company in January 2022. In December 2020, Lexicon Pharmaceuticals concluded their trial on LX9211, while Eliem Therapeutics (UK) Ltd. completed a trial on ETX-018810 in November of the same year. Other completed trials include studies on Naloxone Hydrochloride 0.4 MG/ML by Seema Capoor in October 2020, Galcanezumab by Duke University and BAY1817080 by Bayer both in July 2020, as well as LY3016859 and LX9211 high dose by Eli Lilly and Company and Lexicon Pharmaceuticals respectively also in July 2020. Furthermore, Aptinyx finalized a trial on NYX-2925 at a dosage of 50 mg back in November 2019. These collective efforts reflect the ongoing commitment to finding effective therapies for patients suffering from neuropathic pain.